SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
PROF reported Third quarter ended September 30, 2026 results. The price and volatility reaction is pending.
PROFearnings

Earnings reactions, page 5

Profound Medical Corp. (PROF) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue reached approximately $9.8 million, up 86% year-over-year, consisting of $4.1 million in recurring non-capital revenue and $5.7 million in capital equipment sales.
  • Gross margin expanded to 78% in Q3 2026 compared to 74% in Q3 2025.
  • Operating expenses increased 21% year-over-year to approximately $15.5 million.
  • Cash used in operating activities was approximately $5.0 million, down 56% sequentially from $11.3 million in Q2 2026 and down 48% year-over-year from $9.6 million in Q3 2025.
  • Net loss improved 3% to approximately $7.7 million, or $0.21 per common share, compared to $8.0 million, or $0.26 per common share, in the prior-year quarter.

Guidance

  • Full-year 2026 revenue is projected to be at least $25.0 million.
  • Full-year 2026 gross margin is expected to be 70% or higher.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →